Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 943

1.

[Risk sharing methods in middle income countries].

Inotai A, Kaló Z.

Acta Pharm Hung. 2012;82(1):43-52. Review. Hungarian.

PMID:
22570986
2.

Differential pricing of new pharmaceuticals in lower income European countries.

Kaló Z, Annemans L, Garrison LP.

Expert Rev Pharmacoecon Outcomes Res. 2013 Dec;13(6):735-41. doi: 10.1586/14737167.2013.847367. Review.

PMID:
24219049
3.

[Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].

Hammerman A, Greenberg D.

Harefuah. 2012 Jun;151(6):364-7, 376. Review. Hebrew.

PMID:
22991869
4.

Impact of European pharmaceutical price regulation on generic price competition: a review.

Puig-Junoy J.

Pharmacoeconomics. 2010;28(8):649-63. doi: 10.2165/11535360-000000000-00000. Review.

PMID:
20515079
5.

The economics of parallel trade.

Danzon PM.

Pharmacoeconomics. 1998 Mar;13(3):293-304. Review.

PMID:
10178655
6.

Differential pricing for pharmaceuticals: reconciling access, R&D and patents.

Danzon PM, Towse A.

Int J Health Care Finance Econ. 2003 Sep;3(3):183-205. Review.

PMID:
14625999
7.

European healthcare policies for controlling drug expenditure.

Ess SM, Schneeweiss S, Szucs TD.

Pharmacoeconomics. 2003;21(2):89-103.

PMID:
12515571
8.

Discounts and rebates granted to public payers for medicines in European countries.

Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A.

South Med Rev. 2012 Jul;5(1):38-46. Epub 2012 Jul 23.

9.

Price comparison of high-cost originator medicines in European countries.

Vogler S, Zimmermann N, Babar ZU.

Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):221-230. doi: 10.1080/14737167.2016.1223543. Epub 2016 Oct 11.

PMID:
27658050
10.
11.
12.

The high cost of medicines in Ireland. Is it time to change the pricing mechanism?

Tilson L, McGowan B, Bennett K, Barry M.

Eur J Health Econ. 2004 Dec;5(4):341-4.

PMID:
15452737
13.
14.

Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.

Ioannides-Demos LL, Ibrahim JE, McNeil JJ.

Pharmacoeconomics. 2002;20(9):577-91. Review.

PMID:
12141886
15.

Differences in external price referencing in Europe: a descriptive overview.

Leopold C, Vogler S, Mantel-Teeuwisse AK, de Joncheere K, Leufkens HG, Laing R.

Health Policy. 2012 Jan;104(1):50-60. doi: 10.1016/j.healthpol.2011.09.008. Epub 2011 Oct 19.

PMID:
22014843
16.

[Assessment of the pharmaceutical expenditure in Hungary].

Inotai A, Merész G, Kaló Z.

Acta Pharm Hung. 2010;80(4):162-72. Hungarian.

PMID:
21404477
17.

The End of the International Reference Pricing System?

Persson U, Jönsson B.

Appl Health Econ Health Policy. 2016 Feb;14(1):1-8. doi: 10.1007/s40258-015-0182-5.

PMID:
26112982
18.

Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.

Zaric GS, O'brien BJ.

Health Econ. 2005 Aug;14(8):793-803.

PMID:
15685669
19.

Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.

Stargardt T, Schreyögg J.

Appl Health Econ Health Policy. 2006;5(4):235-47.

PMID:
17249840
20.

Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.

Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, Hill S.

PLoS Med. 2016 May 31;13(5):e1002032. doi: 10.1371/journal.pmed.1002032. eCollection 2016 May.

Supplemental Content

Support Center